These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8622502)

  • 1. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group.
    Hürny C; Bernhard J; Coates AS; Castiglione-Gertsch M; Peterson HF; Gelber RD; Forbes JF; Rudenstam CM; Simoncini E; Crivellari D; Goldhirsch A; Senn HJ
    Lancet; 1996 May; 347(9011):1279-84. PubMed ID: 8622502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.
    ; Rudenstam CM; Zahrieh D; Forbes JF; Crivellari D; Holmberg SB; Rey P; Dent D; Campbell I; Bernhard J; Price KN; Castiglione-Gertsch M; Goldhirsch A; Gelber RD; Coates AS
    J Clin Oncol; 2006 Jan; 24(3):337-44. PubMed ID: 16344321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group.
    Coates AS; Hürny C; Peterson HF; Bernhard J; Castiglione-Gertsch M; Gelber RD; Goldhirsch A
    J Clin Oncol; 2000 Nov; 18(22):3768-74. PubMed ID: 11078489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group.
    Hürny C; Bernhard J; Coates A; Castiglione M; Peterson HF; Gelber RD; Rudenstam CM; Goldhirsch A; Senn HJ
    Ann Oncol; 1994 Jan; 5(1):65-74. PubMed ID: 8172795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
    Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P
    Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group.
    Hürny C; Bernhard J; Gelber RD; Coates A; Castiglione M; Isley M; Dreher D; Peterson H; Goldhirsch A; Senn HJ
    Eur J Cancer; 1992; 28(1):118-24. PubMed ID: 1567662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.
    Bernhard J; Hürny C; Coates AS; Peterson HF; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Senn HJ; Rudenstam CM
    Ann Oncol; 1997 Sep; 8(9):825-35. PubMed ID: 9358933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group.
    Gelber RD; Goldhirsch A; Cavalli F
    Ann Intern Med; 1991 Apr; 114(8):621-8. PubMed ID: 2003707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.